title: Overview of clinical trials with new agents.
authors.affiliation: Nephrology Department, University Hospital of Bicêtre, Kremlin Bicêtre, France.
authors.forename: B
authors.initials: B
authors.lastname: Charpentier
authors.forename: C
authors.initials: C
authors.lastname: Hiesse
authors.forename: A
authors.initials: A
authors.lastname: Durrbach
authors.forename: M
authors.initials: M
authors.lastname: Ammor
authors.forename: F
authors.initials: F
authors.lastname: Von Ey
authors.forename: C
authors.initials: C
authors.lastname: Kechrid
authors.forename: F
authors.initials: F
authors.lastname: Kriaa
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000077552:Basiliximab; D002986:Clinical Trials as Topic; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D006085:Graft Survival; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D015337:Multicenter Studies as Topic; D011993:Recombinant Fusion Proteins; D020123:Sirolimus / Q000627:therapeutic use; D015996:Survival Rate; D014181:Transplantation Immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000077561:Daclizumab; D020123:Sirolimus